MTAP and renal carcinoma: We previously uncovered that MTAP‐deficient renal carcinoma cells become addicted to IGF1R activity to drive oncogenic pathways, so the selective IGF1R inhibitor preferentially impairs their viability and invasiveness (Xu et al, 2019).